An oral antisense oligonucleotide for PCSK9 inhibition
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
A highly potent, chemically modified PCSK9 antisense oligonucleotide formulated with a permeation enhancer was developed for oral administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Ray, K. K., Wright, R. S., Kallend, D., Koenig, W., Leiter, L. A., Raal, F. J., Bisch, J. A., Richardson, T., Jaros, M., Wijngaard, P. L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912387 · Cited by 1,665 · cited 1×
“This reduction is similar to that achieved with Abs (24) and greater than the ~80% reduction observed with siRNA (8, 9, 24).”
ResultEfficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
The chemical evolution of oligonucleotide therapies of clinical utility
Khvorova, A., & Watts, J. K. (2017) · Nature Biotechnology · doi:10.1038/nbt.3765 · Cited by 1,216
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Ray, K. K., Landmesser, U., Leiter, L. A., Kallend, D., Dufour, R., Karakas, M., Hall, T., Troquay, R. P. T., Turner, T., Visseren, F. L. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615758 · Cited by 992
Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Raal, F. J., Kallend, D., Ray, K. K., Turner, T., Koenig, W., Wright, R. S., Wijngaard, P. L. J., Curcio, D., Jaros, M. J., Leiter, L. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913805 · Cited by 818
Cellular uptake and trafficking of antisense oligonucleotides
Crooke, S. T., Wang, S., Vickers, T. A., Shen, W., & Liang, X.-H. (2017) · Nature Biotechnology · doi:10.1038/nbt.3779 · Cited by 582 · cited 1×
“However, it can be expected that GalNAcconjugated ASOs are less prone to such nonproductive uptake because they are taken up primarily by the ASGP receptor (12, 33), supported by the rat data presented here that indicate favorable targetengagement properties upon IJ administration.”
BackgroundCardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Graham, M. J., Lee, R. G., Brandt, T. A., Tai, L.-J., Fu, W., Peralta, R., Yu, R., Hurh, E., Paz, E., McEvoy, B. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701329 · Cited by 573
Self-citation
Cited by
Amyotrophic lateral sclerosis: translating genetic discoveries into therapies
Akçimen, F., Lopez, E. R., Landers, J. E., Nath, A., Chiò, A., Chia, R., & Traynor, B. J. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-023-00592-y · Cited by 234
Expanding biology of PCSK9: roles in atherosclerosis and beyond
Seidah, N. G., & Garçon, D. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01057-z · Cited by 76
PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology
Sundararaman, S. S., Döring, Y., & van der Vorst, E. P. C. (2021) · Biomedicines · doi:10.3390/biomedicines9070793 · Cited by 67
Therapeutic RNA-silencing oligonucleotides in metabolic diseases
Goga, A., & Stoffel, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00407-5 · Cited by 58
PCSK9 in metabolism and diseases
Ajoolabady, A., Pratico, D., Mazidi, M., Davies, I. G., Lip, G. Y. H., Seidah, N., Libby, P., Kroemer, G., & Ren, J. (2025) · Metabolism · doi:10.1016/j.metabol.2024.156064 · Cited by 49
Metadata
- Authors
- Gennemark, P., Walter, K., Clemmensen, N., Rekić, D., Nilsson, C. A. M., Knöchel, J., Hölttä, M., Wernevik, L., Rosengren, B., Kakol-Palm, D., Wang, Y., Yu, R. Z., Geary, R. S., Riney, S. J., Monia, B. P., Isaksson, R., Jansson-Löfmark, R., Rocha, C. S. J., Lindén, D., Hurt-Camejo, E., Crooke, R., Tillman, L., Rydén-Bergsten, T., Carlsson, B., Andersson, U., Elebring, M., Tivesten, A., & Davies, N.
- Venue
- Science Translational Medicine
- Published
- 2021-05-12
- Volume
- 13
- Issue
- 593
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W3160600532
- Cited by
- 120
- References
- 13
- FWCI
- 19.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An oral antisense oligonucleotide for PCSK9 inhibition. https://app.cochat.ai/papers/10.1126/scitranslmed.abe9117
- The paper
- Gennemark, P., Walter, K., Clemmensen, N., Rekić, D., Nilsson, C. A. M., Knöchel, J., Hölttä, M., Wernevik, L., Rosengren, B., Kakol-Palm, D., Wang, Y., Yu, R. Z., Geary, R. S., Riney, S. J., Monia, B. P., Isaksson, R., Jansson-Löfmark, R., Rocha, C. S. J., Lindén, D., . . . Davies, N. (2021). An oral antisense oligonucleotide for PCSK9 inhibition. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.abe9117
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.